Lord, Abbett & Co
CLDX icon

Lord, Abbett & Co’s Celldex Therapeutics CLDX Stock Holding History

Lord, Abbett & Co’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-75,758
Closed -$17.8M – 886
2015
Q4 		$17.8M Buy
75,758
+54,206
+252% +$11.8M 0.05% 462
2015
Q3 		$3.41M Sell
21,552
-95,276
-82% -$27M 0.01% 793
2015
Q2 		$44.2M Sell
116,828
-38,307
-25% -$15.2M 0.12% 281
2015
Q1 		$64.9M Sell
155,135
-22,851
-13% -$8.17M 0.16% 180
2014
Q4 		$48.7M Buy
177,986
+73,504
+70% +$18.3M 0.12% 241
2014
Q3 		$20.3M Sell
104,482
-8,016
-7% -$1.75M 0.05% 489
2014
Q2 		$27.5M Buy
112,498
+81,301
+261% +$18.4M 0.06% 439
2014
Q1 		$8.27M Sell
31,197
-36,374
-54% -$13.9M 0.02% 700
2013
Q4 		$24.5M Sell
67,571
-34,613
-34% -$13.3M 0.05% 475
2013
Q3 		$54.3M Sell
102,184
-20,987
-17% -$7.2M 0.13% 228
2013
Q2 		$28.8M Buy
+123,171
New +$24.3M 0.07% 422

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lord, Abbett & Co's CLDX Position: Q1 2016 in Review

Lord, Abbett & Co sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 75,758 shares — an estimated $17.8M sold.

Lord, Abbett & Co first reported a position in CLDX in Q2 2013 and held it in 11 quarters. The position peaked at $64.9M in Q1 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • Lord, Abbett & Co reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Lord, Abbett & Co sold 75,758 Celldex Therapeutics shares in Q1 2016, an estimated $17.8M.
  • Lord, Abbett & Co first reported a position in Celldex Therapeutics in Q2 2013 and held it in 11 quarters.
  • Lord, Abbett & Co's Celldex Therapeutics position peaked at $64.9M in Q1 2015.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Lord, Abbett & Co's 13F filing for Q1 2016, filed 16 May 2016.